Exact Sciences Stock Fair Value Calculator – Envestnet Asset Management Decreases Stake in Exact Sciences Co.

☀️Trending News

Exact Sciences ($NASDAQ:EXAS) Co. is a publicly traded company that specializes in molecular diagnostic testing. It is known for its flagship product, Cologuard, which is a non-invasive colon cancer screening test. The company operates in the healthcare industry and is considered a leader in the field of early cancer detection. Recently, Envestnet Asset Management Inc., a financial services company, decreased its stake in Exact Sciences Co. This news has caused some buzz in the stock market, as it is seen as a significant move by a major investor. Envestnet Asset Management Inc. is a prominent player in the financial industry and has a significant amount of influence in the stock market. The fact that they have decided to decrease their stake in Exact Sciences Co. may be seen as a sign of their lack of confidence in the company’s future performance. This decrease in stake could also be seen as a reflection of the current market conditions and the overall sentiment towards Exact Sciences Co. As with any stock, the value of Exact Sciences Co. is subject to market fluctuations and investor sentiment. By reducing their stake, Envestnet Asset Management Inc. may be indicating that they believe the stock may not perform well in the near future.

However, it is also important to note that Envestnet Asset Management Inc. has not completely divested from Exact Sciences Co. They still hold a significant stake in the company, which could mean that they still see potential for growth and value in the stock. Overall, this news may cause some uncertainty among investors and could potentially lead to a decrease in the value of Exact Sciences Co. However, it is important to remember that stock prices are influenced by various factors and can change rapidly. As a leader in molecular diagnostic testing and with its innovative products, Exact Sciences Co. may still have a strong future ahead despite this decrease in stake by Envestnet Asset Management Inc.

Market Price

Envestnet Asset Management Inc. has recently decreased its stake in Exact Sciences Co., a move that has raised some eyebrows in the investment community. This news comes after EXACT SCIENCES stock opened at $68.68 on Wednesday and closed at $67.77, marking a decrease of 1.4% from the previous day’s closing price of $68.73. The decrease in Envestnet’s stake in Exact Sciences Co. has caused some concern among investors, as the company has been performing well in the market. With a steady increase in stock value over the past few months, Exact Sciences Co. has been a favorite among investors looking for growth potential.

However, this decrease in stake could be seen as a strategic move by Envestnet Asset Management Inc. to reallocate its investments. As a financial services company, Envestnet may have decided to diversify its portfolio and reduce its exposure in the healthcare industry, where Exact Sciences Co. operates. Exact Sciences Co. specializes in developing and commercializing non-invasive cancer screening tests, which have garnered significant attention and investment in recent years. This market is expected to continue growing, but Envestnet may have their sights set on other industries where they see more potential for growth. While Envestnet’s decreased stake in Exact Sciences Co. may cause some initial concern among investors, it is important to note that the company still holds a significant portion of shares in the company. This move does not necessarily reflect any negative outlook on Exact Sciences Co., but rather a strategic decision by Envestnet to diversify their investments. In conclusion, the decrease in Envestnet’s stake in Exact Sciences Co. may have caused some ripples in the market, but it should not be seen as a cause for alarm. As with any investment decision, it is important to consider the company’s overall performance and potential for growth, rather than focusing on short-term fluctuations. Only time will tell how this move will affect both Exact Sciences Co. and Envestnet, but it is a clear indication of the constantly evolving nature of the financial market. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Exact Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Exact Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Exact Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Exact Sciences are shown below. More…

Analysis – Exact Sciences Stock Fair Value Calculator

After analyzing EXACT SCIENCES‘s basic principles, I have determined that this company has a strong foundation and potential for growth. Their focus on developing accurate and non-invasive cancer screening tests is both socially responsible and financially promising. Based on our proprietary Valuation Line, we have calculated that the intrinsic value of a share of EXACT SCIENCES is around $88.9. This takes into account various factors such as the company’s financial health, market trends, and potential for future earnings. As of now, EXACT SCIENCES’s stock is being traded at $67.77. This means that it is currently undervalued by approximately 23.8%. This presents an opportunity for investors to purchase shares at a lower price and potentially see a significant return on their investment in the future. Overall, EXACT SCIENCES has a solid business model and strong prospects for growth. With an undervalued stock price, it may be a wise choice for investors looking to add a promising company to their portfolio. However, as with any investment, it is important to conduct thorough research and consider all potential risks before making a decision. More…

Peers

The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.

Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.

– Myriad Genetics Inc ($NASDAQ:MYGN)

Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.

Summary

Envestnet Asset Management Inc. has reduced its ownership in Exact Sciences Co, according to recent filings. This could suggest a lack of confidence in the company’s financial performance or future prospects. Envestnet’s actions could also reflect a strategy to diversify its investment portfolio. It is worth noting that Exact Sciences has experienced significant growth in recent years, especially with the success of its cancer screening test, Cologuard.

However, investors may want to closely monitor any changes in ownership and keep an eye on the company’s financial reports to make informed decisions about their investment in Exact Sciences.